MarketPeel
Insider Trading Intelligence
Pricing
…
JC

James George Chopas

APLS
VP/CHIEF ACCOUNTING OFFICER · APELLIS PHARMACEUTICALS, INC. · CIK 0001836430
FILING MIX · LIFETIME39%/61%
BUYS
22
SELLS
34
TOTAL VALUE
$2.30M
COMPANIES
1
ACTIVE SINCE
Aug 2021
HOLDINGS NOW
0
AVG SELL PX
$38.15
TRADE KIND
SHOWING 56 / 56
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
16 backtested trades · 8 horizons · 19 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by James George Chopas, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d16+56.25%-0.39%+0.89%-1.27%-1.73%—
14d16+50.00%-2.17%+1.37%-3.54%-1.61%—
30d16+56.25%-6.57%+1.25%-7.83%-4.60%—
60d16+87.50%-15.17%+1.10%-16.26%-16.79%—
90d16+62.50%+5.28%+2.64%+2.64%-21.89%—
180d16(3 pending)+84.62%-20.58%+9.34%-29.93%-38.80%—
1y16(5 pending)+100.00%-35.27%+21.47%-56.74%-49.48%—
2y16(11 pending)+100.00%-55.29%+46.72%-102.01%-100.02%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
APLS · 0 shares · as of May 14, 2026
016,48932,97849,46665,95520222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 22 buys / 34 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
11,250——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
8,394——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
9,444——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
20,853——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
5,625——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
2,406——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
16,150——16,150May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
15,114——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
12,086——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
21,750——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
6,250——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
16,150——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
65,955——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,625——5,625May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
8,075——8,075May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
8,394——8,394May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
8,075——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
4,156——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
16,150——65,955Jan 28, 2026Jan 30, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
2,064$21.77$44.9K49,805Jan 22, 2026Jan 23, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
726$19.79$14.4K51,869Jan 20, 2026Jan 21, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
873$22.19$19.4K52,595Jan 13, 2026Jan 15, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
189$24.19$4.6K53,468Sep 15, 2025Sep 16, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
548$28.08$15.4K53,657Sep 2, 2025Sep 3, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,250——54,205Jun 18, 2025Jun 20, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
11,250$19.39$218.1K11,250Jun 9, 2025Jun 11, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
183$24.82$4.5K47,955Mar 17, 2025Mar 18, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
1,096$30.43$33.3K48,138Jan 22, 2025Jan 23, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,591——49,234Jan 21, 2025Jan 21, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
715$29.96$21.4K36,643Jan 17, 2025Jan 21, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
783$28.70$22.5K37,358Jan 13, 2025Jan 14, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
192$36.21$7.0K38,141Sep 16, 2024Sep 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
550$39.49$21.7K38,333Sep 3, 2024Sep 4, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
184$56.46$10.4K38,883Mar 15, 2024Mar 18, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
1,061$65.00$69.0K39,067Jan 22, 2024Jan 23, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
864$66.81$57.7K40,128Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,086$66.30$801.3K12,086Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
8,312——40,992Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
132$46.04$6.1K32,680Oct 23, 2023Oct 24, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
2,500——32,812Sep 14, 2023Sep 18, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
551$41.23$22.7K30,312Aug 31, 2023Sep 1, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,044——31,197Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
334$58.50$19.5K30,863Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,737——5,737Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
919$52.05$47.8K27,153Jan 20, 2023Jan 24, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,114$52.66$795.9K15,114Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,621——28,072Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
130$58.00$7.5K18,451Oct 20, 2022Oct 24, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
VP/Chief Accounting Officer
558$58.84$32.8K18,581Aug 30, 2022Aug 31, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,892——9,892Jan 21, 2022Jan 25, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,974——15,456Jan 21, 2022Jan 25, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,657——19,139Jan 21, 2022Feb 7, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,116——15,116Jan 21, 2022Feb 7, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
882——8,482Oct 20, 2021Oct 27, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,600——7,600Aug 30, 2021Sep 1, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
21,750——21,750Aug 30, 2021Sep 1, 2021 ↗View →
Other insiders · APLS
Loading peer insiders…
About this filer
CIK 0001836430
ROLE
VP/Chief Accounting Officer
PRIMARY
APLS
COMPANIES
1
ACTIVE SINCE
Aug 2021
MARKETPEEL · /INSIDER/0001836430DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback